What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
The scientist’s investigation covers issues in Internal medicine, Immunology, Chronic lymphocytic leukemia, Gastroenterology and Paroxysmal nocturnal hemoglobinuria.
His Internal medicine research incorporates themes from Surgery and Oncology.
Within one scientific family, Peter Hillmen focuses on topics pertaining to Stem cell marker under Immunology, and may sometimes address concerns connected to Single-nucleotide polymorphism, Locus, Hematological malignancy, Disease causation and Genome-wide association study.
He interconnects Monoclonal B-cell lymphocytosis, Monoclonal and Minimal residual disease in the investigation of issues within Chronic lymphocytic leukemia.
His study looks at the relationship between Gastroenterology and fields such as Hazard ratio, as well as how they intersect with chemical problems.
His Paroxysmal nocturnal hemoglobinuria study integrates concerns from other disciplines, such as Hemolysis, Aplastic anemia, Eculizumab, Acquired hemolytic anemia and Platelet activation.
His most cited work include:
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines (2519 citations)
- Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. (1170 citations)
- The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. (1126 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Chronic lymphocytic leukemia, Oncology, Immunology and Paroxysmal nocturnal hemoglobinuria.
The various areas that Peter Hillmen examines in his Internal medicine study include Gastroenterology and Surgery.
His work carried out in the field of Chronic lymphocytic leukemia brings together such families of science as Adverse effect, Cancer research, Clinical trial and Minimal residual disease.
His Oncology research integrates issues from Idelalisib, Chemoimmunotherapy, Ofatumumab, Venetoclax and Relapsed refractory.
Immunology is frequently linked to Disease in his study.
His studies deal with areas such as Hemolysis, Hemoglobinuria, Anemia, Eculizumab and Thrombosis as well as Paroxysmal nocturnal hemoglobinuria.
He most often published in these fields:
- Internal medicine (66.60%)
- Chronic lymphocytic leukemia (33.40%)
- Oncology (31.78%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (66.60%)
- Chronic lymphocytic leukemia (33.40%)
- Oncology (31.78%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Chronic lymphocytic leukemia, Oncology, In patient and Ibrutinib are his primary areas of study.
His Internal medicine study often links to related topics such as Gastroenterology.
His study in Chronic lymphocytic leukemia is interdisciplinary in nature, drawing from both Cancer research and Bruton's tyrosine kinase.
His Oncology research is multidisciplinary, incorporating perspectives in Chlorambucil, Chemoimmunotherapy, Ofatumumab, Relapsed refractory and Fludarabine.
His Chlorambucil research includes themes of Long term follow up, Five year follow up and Immunology.
His Ibrutinib study incorporates themes from Refractory, First line treatment, Tyrosine kinase, Lymphocytosis and Tyrosine-kinase inhibitor.
Between 2018 and 2021, his most popular works were:
- Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study (117 citations)
- Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. (69 citations)
- Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. (67 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Peter Hillmen mainly focuses on Internal medicine, Chronic lymphocytic leukemia, Oncology, Ibrutinib and Rituximab.
Peter Hillmen frequently studies issues relating to Gastroenterology and Internal medicine.
Peter Hillmen has researched Gastroenterology in several fields, including Hemolysis and Incidence.
His study in the field of Venetoclax is also linked to topics like In patient.
His Ibrutinib research is multidisciplinary, relying on both Chlorambucil, Refractory, Ofatumumab and Survival rate.
His work deals with themes such as Idelalisib and Overall survival, which intersect with Rituximab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
